RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have received a consensus recommendation of “Hold” from the thirteen research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.50.

A number of research firms have recently issued reports on RAPT. Stifel Nicolaus reiterated a “hold” rating and set a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday. Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a research note on Monday. Wells Fargo & Company lowered their target price on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday. HC Wainwright restated a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday. Finally, UBS Group lowered their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RAPT. Point72 Asset Management L.P. raised its holdings in shares of RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after buying an additional 706,900 shares during the last quarter. Kingdon Capital Management L.L.C. raised its holdings in shares of RAPT Therapeutics by 55.3% during the first quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after purchasing an additional 534,172 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of RAPT Therapeutics by 188.7% during the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock worth $2,428,000 after purchasing an additional 520,368 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of RAPT Therapeutics by 4,183.3% during the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock worth $1,424,000 after purchasing an additional 456,275 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of RAPT Therapeutics by 21.2% during the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after purchasing an additional 436,629 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $1.28 on Friday. The firm’s 50 day moving average price is $1.96 and its 200-day moving average price is $3.05. RAPT Therapeutics has a 52-week low of $1.25 and a 52-week high of $27.35. The company has a market cap of $44.68 million, a PE ratio of -0.46 and a beta of 0.33.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.